

PERSONAL INFORMATION

Kieran Breen

WORK EXPERIENCE

November 2015–February 2018

Director of Research

Brain Tumour Research (United Kingdom)

Development, implementation and evaluation of a comprehensive organisational research strategy associated with an increase in the number of research centres funded by the charity

February 2018–Present

Head of Research and Innovation

St Andrews Healthcare (United Kingdom)

Design, implementation and monitoring of a clinical research strategy within a secure psychiatric institution with a particular use of patient clinical data

July 2013–Present

Patient Representative on the Committee for Advanced Therapies

European Medicines Agency (United Kingdom)

Classification of Advanced Therapeutic Medicinal Products

Provision of expert scientific advice as co-rapporteur (pre-clinical)

Reviewer of market authorisation application for new Advanced Therapeutic Medicinal Products

Representative on the Patient and Consumers Working Party

Representative on Registries Task Force

May 2014–May 2015

Head of Programmes and Evaluation

National Cancer Research Institute (United Kingdom)

Analysis and publication of the UK National Cancer Research Database including development of research evaluation tools and methodologies to assess project performance and partnership impact

March 2005–February 2014

Director of Research and Innovation

Parkinsons UK (United Kingdom)

Direction, implementation and evaluation of the charity's research strategy with the establishment of an international collaborative working group to develop a research programme for the use of patient databases using a common cloud-based IT data platform including participants from academia, regulatory bodies and data experts

January 2002–March 2003

Visiting Fellow

CNRS (France)

Development of a collaborative research programme on the biochemical mechanisms underlying Alzheimer's disease

January 1998–March 2005

Director of Alzheimers Disease Research Centre

University of Dundee (United Kingdom)

Establishment and direction of a multidisciplinary research centre consisting of 21 individual research groups of clinical, social and laboratory-based researchers

September 1992–March 2005

Senior Lecturer in Biological Psychiatry

University of Dundee (United Kingdom)

Direction of multidisciplinary dementia-focussed neuroscience laboratory with an annual budget of over £150k with the supervision of 12 grant-funded PhD students and 6 postdoctoral researchers and

external examination of 20 PhD students in the UK and Europe

January 1990–September 1992

Senior Research Fellow

University College Dublin (Ireland)

Prestigious personal research fellowship to develop academic career

May 1987–December 1989

Postdoctoral research fellow

St Georges Hospital Medical School, London (United Kingdom)

Research into the molecular basis of neurodegeneration in Alzheimer's disease

EDUCATION AND TRAINING

October 1980–July 1984

Bachelor of Science (Honours)

University College Dublin (Ireland)

Pharmacology and toxicology

July 1984–May 1987

Ph.D.

University College Dublin (Ireland)

Neuroscience

October 2005–December 2006

Postgraduate Certificate in Business Administration

The Open University (United Kingdom)

ADDITIONAL INFORMATION

Expertise

Pharmacology and toxicology

Molecular and cell biology

Research communications

Design and execution of clinical studies

Patient and consumer communication

Publications

Since 2010

Anthony J, Kinnafick FE, Papathomas A, Breen KC. (2020). Physical Activity for Adolescents with Serious Mental Illness: A Systematic Scoping Review. *International Review of Sport and Exercise Psychology*. In press

Hancock-Johnson E, Staniforth C, Pomroy L, Breen KC (2019). Adolescent inpatient completers of Dialectical Behaviour Therapy. *J Forensic Practice*. In press

Breen KC (2018). Role of the blood brain barrier in the development of new therapies for the treatment of brain tumours. *Oncol News* 12(3):74-75

Breen KC (2017). Drug repurposing - a novel approach for the treatment of brain tumours. *Oncol News* 12(1):14-15

Breen KC (2017) The importance of tissue banking for our understanding of brain tumours 11(6)170-171

Breen KC (2016). Patient involvement in clinical trials. *Oncol News* 11(5):143-144

Breen KC (2016). The development and treatments of brain metastases. *Oncol News* 11(4)102-103

Breen KC (2016). Brain Tumour Research – the Research Centre Model. *Oncol News*. 11(2)42-43

Breen KC (2016). New therapeutic approaches for the treatment of brain tumours *Oncol. News*. 11:5-6

Stephenson D, Hu MT, Romero K, Breen K et al. (2015). Precompetitive Data Sharing as a Catalyst to

Address Unmet Needs in Parkinson's Disease. *J Parkinsons Dis.* 2015;5(3):581-94

Drutyte G, Forjaz MJ, Rodriguez-Blazquez C, Martinez-Martin P, Breen KC. (2014). What impacts on the stress symptoms of Parkinson's carers? Results from the Parkinson's UK Members' Survey. *Disabil Rehabil.* 36:199-204

Breen, KC. (2014). Developing the next generation of Parkinson's disease therapies. *Adv Clin Neurosci Rehab.* 13(1): 9-11

Breen KC, Drutyte G. (2013). Non-motor symptoms of Parkinson's disease: the patient's perspective. *J Neural Transm.* 120:531-5.

Scerri C, Stewart CA, Balfour DJ, Breen KC.(2012), Nicotine modifies in vivo and in vitro rat hippocampal amyloid precursor protein processing in young but not old rats. *Neurosci Lett.* 514(1):22-6

Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y. (2011). Helicobacter pylori eradication for Parkinson's disease. *Cochrane Database Syst Rev.* 11:CD008453

Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y. (2011). Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. *Cochrane Database Syst Rev.* 11:CD008454.

Rees K, Stowe R, Patel S, Ives N, Breen K, Ben-Shlomo Y, Clarke CE.(2011). Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials. *Cochrane Database Syst Rev.* 11:CD008535

- Projects**
- Establishment of a multi-centre prospective study of people with Parkinson's involving 4,000 people located in 20 UK centres
 - Development of a trans-national consortium involving regulatory agencies, public health bodies, pharmaceutical companies and patient representatives to combine patient data to develop a mathematical modeling process to understand Parkinson's progression
 - Member of the steering committee of an EU FP7-funded programme with academic and industrial partners to develop mathematical models for disease progression
 - Member of the steering bodies of two international clinical trials to assess the impact of non-motor symptoms on the quality of life of people with Parkinson's with associated commissioning and designing projects on specific research programmes (sleep, depression and dementia)

Memberships

- Other Relevant Information**
- UK Department of Health working group on the repurposing of off-patent medicines
 - Parkinson's disease coordinating committee of the US Critical Path Institute
 - Strategic Research Agenda Working Group of the EU Joint Programme for Neurodegenerative Diseases
 - Scientific Advisor - European Parkinson's Disease Association (2012 - date)